Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

245 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Immuron Q3 FY23 Business Update Presentation

April 19, 2023 at 06:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar to be held today at 11:00 am (AEST).

The Investor Presentation includes the following material information (unaudited):

Worldwide sales for the two weeks 1 to 14 April 2023 were A$320,000.
This represents 37% of sales for the whole of Q3 FY23 of A$875,000.
Sales FY23 YTD to 14 April 2023 of A$1,779,000 represents a 233% increase over the corresponding prior period YTD to 14 April 2022 of $534,000.

Investors are invited to join the webcast and Q&A hosted by Immuron CEO Steven Lydeamore.

To register for the webinar, please click on this link:

https://us02web.zoom.us/webinar/register/WN_TpvaXZZ1QDG1FnZdXdtSGA

After registering, you will receive a confirmation email containing information to join the webinar.

A copy of the presentation slide deck is available on the Company’s website.

https://www.immuron.com.au/corporate-presentations/

Approved for release by the CEO.

COMPANY CONTACT:

Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com